Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:activities |
stimulates immune response
|
| gptkbp:advocates_for |
required for participation
|
| gptkbp:analyzes |
clinical researchers
|
| gptkbp:benefits |
improved survival rates
|
| gptkbp:clinical_trial |
gptkb:2021
gptkb:United_States Phase 1 Moderna, Inc. to be published overall survival open-label study Phase 1 and beyond pending results |
| gptkbp:collaborations |
gptkb:Merck_&_Co.
academic partnerships |
| gptkbp:committee |
independent committee
|
| gptkbp:data_type |
adaptive immune response
|
| gptkbp:developed_by |
Moderna, Inc.
|
| gptkbp:feedback |
collected during trials
|
| gptkbp:form |
gptkb:item
|
| gptkbp:frequency |
multiple doses
|
| https://www.w3.org/2000/01/rdf-schema#label |
Moderna's m RNA-4157
|
| gptkbp:impact |
potential to change cancer treatment paradigm
|
| gptkbp:indication |
gptkb:healthcare_organization
|
| gptkbp:investment |
cancer therapeutics
|
| gptkbp:is_effective_against |
to be determined
|
| gptkbp:is_monitored_by |
during and after treatment
|
| gptkbp:is_tested_for |
tumor mutation burden
|
| gptkbp:is_vulnerable_to |
ongoing research
by healthcare professionals messenger RNA refrigerated conditions |
| gptkbp:manager |
injection
|
| gptkbp:moral |
obtained
|
| gptkbp:objective |
evaluate safety and efficacy
|
| gptkbp:part_of |
cancer immunotherapy
|
| gptkbp:platform |
m RNA technology
|
| gptkbp:population |
adults
|
| gptkbp:products |
submitted to FDA
|
| gptkbp:project |
early clinical development
|
| gptkbp:publishes |
peer-reviewed journals
|
| gptkbp:receives_funding_from |
public and private funding
|
| gptkbp:recruitment |
ongoing
|
| gptkbp:regulatory_compliance |
not approved yet
|
| gptkbp:research_areas |
oncology
various academic institutions |
| gptkbp:research_focus |
personalized cancer vaccines
|
| gptkbp:safety_features |
under evaluation
|
| gptkbp:scientific_goals |
advancing cancer treatment
|
| gptkbp:shipping_options |
lipid nanoparticles
|
| gptkbp:side_effect |
to be assessed
|
| gptkbp:status |
in development
|
| gptkbp:student_enrollment |
specific genetic markers
|
| gptkbp:supply_chain |
managed by Moderna
|
| gptkbp:target_audience |
patients with melanoma
|
| gptkbp:targets |
gptkb:healthcare_organization
neoantigens |
| gptkbp:technology |
therapeutic vaccine
|
| gptkbp:type |
gptkb:vaccine
|
| gptkbp:year |
gptkb:2023
|
| gptkbp:bfsParent |
gptkb:m_RNA_cancer_vaccine
|
| gptkbp:bfsLayer |
6
|